- Home
- FBRX vs RGR Comparison
FBRX vs RGR Comparison
Compare FBRX & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRX | RGR |
|---|---|---|
| Founded | N/A | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 521.9M |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | FBRX | RGR |
|---|---|---|
| Price | $27.32 | $42.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $67.00 | $43.00 |
| AVG Volume (30 Days) | ★ 385.9K | 132.5K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.09% |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $546,057,000.00 |
| Revenue This Year | N/A | $2.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.94 |
| 52 Week Low | $6.50 | $28.33 |
| 52 Week High | $35.80 | $48.21 |
Technical Indicators
Market Signals| Indicator | FBRX | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 63.86 |
| Support Level | $26.67 | $36.28 |
| Resistance Level | $31.71 | $44.10 |
| Average True Range (ATR) | 3.16 | 0.85 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 20.92 | 89.33 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.